Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Mathias Schulz"'
Publikováno v:
Sensors, Vol 24, Iss 9, p 2750 (2024)
Biometric authentication plays a vital role in various everyday applications with increasing demands for reliability and security. However, the use of real biometric data for research raises privacy concerns and data scarcity issues. A promising appr
Externí odkaz:
https://doaj.org/article/888c4df8cffb4a768452ccabc6b1a097
Autor:
Maria Vutcovici Nicolae, Mei Dong, Teraneh Z. Jhaveri, Laura De Benedetti, Hanane Khoury, Lee Stern, Mellissa Williamson, Jason Beal, Matthew Radford, Mindy Chen, Siu-Chi Chang Sun, Evelyn Rustia, Mathias Schulz, Giri Ramsingh, Eduardo Sabate
Publikováno v:
HemaSphere, Vol 7, p e22327be (2023)
Externí odkaz:
https://doaj.org/article/e1220617744643478f1d954fcb3dccc9
Autor:
Timo Lausen, Stefan Keil, Norman Dodel, Mathias Schulz, Andrea Corna, Gunther Zeck, Andreea-Elena Cojocaru, Roland Thewes
Publikováno v:
2022 IEEE Biomedical Circuits and Systems Conference (BioCAS).
Autor:
Shirish M. Gadgeel, Dong Wan Kim, Alice T. Shaw, Fabrice Barlesi, Lucio Crinò, Filippo de Marinis, Ravindra Gupta, James Chih-Hsin Yang, Anne-Marie C. Dingemans, Sai-Hong Ignatius Ou, Vlatka Smoljanovic, Shiyao Liu, Mathias Schulz
Publikováno v:
Lung Cancer: Targets and Therapy. 10:125-130
Introduction Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American NP28761 (NCT01871805) studies.
Autor:
Brian C. Sauer, Anthony Masaquel, Chunyang Li, Ahmad Halwani, Elisha De Long-Sieg, Mary Halloran, Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Christina Yong, Mathias Schulz, Deborah Morreall, Hsu-Chih Chien
Publikováno v:
Future oncology (London, England). 17(4)
Aim: To describe practices and outcomes in veterans with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Using Veteran Affairs Cancer Registry System and electronic health record data, we identified relapsed/refractory diffuse
Autor:
Per-Olof Thuresson, Ella X Du, Anthony Masaquel, Federico Felizzi, Jia Li, Keith A. Betts, Ibou Dieye, Mathias Schulz
Publikováno v:
Journal of comparative effectiveness research. 9(14)
Aim: To evaluate the cost–effectiveness of polatuzumab vedotin (pola) + bendamustine + rituximab (BR) in relapsed/refractory diffuse large B-cell lymphoma based on the GO29365 trial from a US payer’s perspective. Materials & methods: A partitione
Autor:
Frank Griesinger, MD, PhD, Wilfried E.E. Eberhardt, MD, PhD, Wolfgang M. Brueckl, MD, PhD, Horst-Dieter Hummel, MD, PhD, Bastian Jaeschke, MD, Jens Kern, MD, Claas Wesseler, MD, Martina Jänicke, PdD, Annette Fleitz, PhD, Stefan Zacharias, PhD, Annette Hipper, PhD, Annika Groth, MD, PhD, Wilko Weichert, MD, PhD, Steffen Dörfel, Volker Petersen, MD, Jan Schröder, MD, Jochen Wilke, MD, Martin Sebastian, MD, Michael Thomas, MD, PhD, Juliana Ababei, Jürgen Alt, Andreas Ammon, Jürgen Anhuf, Ivo Azeh, Stefan Bauer, Dirk Behringer, Winfried Berger, Christiane Bernhardt, Mathias Bertram, Michael Boesche, Sabine Bohnet, Harald-Robert Bruch, Wolfgang Brückl, Ulrike Burkhard-Meier, Petros Christopoulos, Klaus-Ulrich Däßler, Maike de Wit, Tobias Dechow, Reinhard Depenbusch, Lutz Dietze, Markus Dommach, Wilfried Eberhardt, Corinna Elender, Wolfgang Elsel, Till-Oliver Emde, Martin Faehling, Thomas Fietz, Jürgen R. Fischer, Dimitri Flieger, Anke Freidt, Werner Freier, Christian Frenzel, Florian Fuchs, Roswitha Fuchs, Tobias Gaska, Wolfgang Gleiber, Christian Grah, Frank Griesinger, Christian Grohé, Matthias Groschek, Björn Güldenzoph, Andreas Günther, Siegfried Haas, Matthias Hackenthal, Volker Hagen, Lars Hahn, Verena Hannig Carla, Richard Hansen, Hanns-Detlev Harich, Monika Heilmann, Kathrin Heinrich, Christiane Hering-Schubert, Jörg Heßling, Petra Hoffknecht, Patricia Hortig, Gerdt Hübner, Horst-Dieter Hummel, Ulrich Hutzschenreuter, Thomas Illmer, Georg Innig, Bastian Jaeschke, Christian Junghanß, Ulrich Kaiser, Haytham Kamal, Kato Kambartel, Jens Kern, Martin Kimmich, Dorothea Kingreen, Heinz Kirchen, Martine Klausmann, Ortwin Klein, Konrad Kokowski, Wolfgang Körber, Cornelius Kortsik, Dirk Koschel, Benoit Krämer, Beate Krammer-Steiner, Eckart Laack, Christof Lamberti, Rumo David Leistner, Christoph Losem, Andreas Lück, Christoph Maintz, Kerstin Martin, Dirk Medgenberg, Martin Metzenmacher, Christian Meyer zum Büschenfelde, Philipp Meyn, Enno Moorahrend, Annette Müller, Lothar Müller, Michael Neise, Holger Nückel, Arnd Nusch, Tobias Overbeck, Henning Pelz, Volker Petersen, Bettina Peuser, Margarete Plath, Winfried J. Randerath, Jacqueline Rauh, Martin Reck, Dietmar Reichert, Niels Reinmuth, Marcel Reiser, Roland Repp, Daniel Reschke, Achim Rittmeyer, Yolanda Rodemer, Sandra Sackmann, Parvis Sadjadian, Reiner Sandner, Annette Sauer, Harald Schäfer, Christoph Schaudt, Rudolf Schlag, Burkhard Schmidt, Stephan Schmitz, Jan Schröder, Michael Schroeder, Mathias Schulze, Christian Schumann, Wolfgang Schütte, Martin Schwaiblmair, Florian Schwindt Peter, Martin Sebastian, Bernd Seese, Gernot Seipelt, Thomas Sorgenfrei, Johannes Steiff, Heike Steiniger, Tanja Trarbach, Amanda Tufman, Jens Uhlig, Ursula Vehling-Kaiser, Eyck von der Heyde, Ulla von Verschuer, Cornelius Waller, Thomas Wehler, Georg Weißenborn, Florian Weißinger, Martin Wermke, Claas Wesseler, Jörg Wiegand, Stefan Wilhelm, Jochen Wilke, Mark-Oliver Zahn, Matthias Zaiss, Matthias Zeth
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100626- (2024)
Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNS
Externí odkaz:
https://doaj.org/article/193c505adea04fdda590997c6e7e69c0
Autor:
Alice T. Shaw, Filippo de Marinis, Ahmed Kotb, Fabrice Barlesi, Sai-Hong Ignatius Ou, Shiyao Liu, Shirish M. Gadgeel, Lucio Crinò, Ravindra Gupta, Anne-Marie C. Dingemans, Mathias Schulz, James Chih-Hsin Yang, Dong Wan Kim
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 118(1), 38-42. Nature Publishing Group
British Journal of Cancer, 118(1), 38-42. Nature Publishing Group
Background: We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the exte
Autor:
Mathias Schulz-Senft, Sindu Shree, Nils H. Alsleben, Rainer Adelung, Anne Staubitz, Yogendra Kumar Mishra
Publikováno v:
ACS Applied Materials & Interfaces. 9:38000-38007
A self-reporting polythiourethane/tetrapodal-ZnO (PTU/T-ZnO) composite is produced using spiropyran as an additive at a concentration as low as 0.5 wt %. Exposure to heat, UV light and mechanical force caused the spiropyran to undergo reversible isom
Publikováno v:
Zeitschrift für Orthopädie und Unfallchirurgie. 155:169-176
Introduction Patellar dislocation is one of the commonest knee injuries in adolescents. Although treatment usually leads to good results, the influence of anatomical and functional factors on therapeutic strategy has been underestimated, especially i